ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium
Business Wire•08/10/2026•08:30 ET
0
Key Highlights
- ➤ImmunityBio (IBRX) to participate in Piper Sandler oncology symposium October 16, 2026
- ➤Patrick Soon-Shiong will join a 25-minute virtual fireside chat
- ➤Company highlights continued ANKTIVA advancement and broader immunotherapy pipeline
Expert Statements
Patrick Soon-Shiong, Founder, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio
“We welcome the opportunity to join Piper Sandler and the investment community to discuss ImmunityBio’s progress and our vision for transforming cancer care by activating the body’s innate and adaptive immune systems.”
Patrick Soon-Shiong, Founder, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio
“With the continued advancement of ANKTIVA(® )(nogapendekin alfa inbakicept-pmln) and our broader immunotherapy pipeline, we remain focused on translating innovative science into durable treatment options for patients with difficult-to-treat diseases.”
ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium
ImmunityBio, Inc. (NASDAQ: IBRX ), a commercial-stage immunotherapy company, today announced that Dr. Patrick Soon-Shiong, its Founder, Executive Chairman and Global Chief Scientific and Medical Officer, will participate virtually in a fireside chat at the Piper Sandler Virtual Oncology Symposium, taking place October 15-16, 2026.
Get started
Create a free account to read the full story.